Chronic β-adrenoceptor antagonist treatment controls cardiovascular remodeling in heart failure in the aging spontaneously hypertensive rat

Journal of Cardiovascular Pharmacology

Volumn 58, Issue 4, 2011, Pages 424-431

  Chan, Vincent ^a,b,c   Fenning, Andrew ^a,d   Hoey, Andrew ^b   Brown, Lindsay ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF SOUTHERN QUEENSLAND   (Australia)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^d CENTRAL QUEENSLAND UNIVERSITY   (Australia)

Author keywords

adrenoceptor antagonist; heart failure; hypertension; hypertensive rats; remodeling; spontaneously

Indexed keywords

COLLAGEN; METOPROLOL;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR FUNCTION; CELL INFILTRATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIASTOLIC DYSFUNCTION; DRUG DOSE TITRATION; ECHOCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; HEART DILATATION; HEART FAILURE; HEART LEFT VENTRICLE; HEART MUSCLE COMPLIANCE; HEART MUSCLE FIBROSIS; HEART MUSCLE POTENTIAL; HEART PAPILLARY MUSCLE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEART VOLUME; HYPERTENSION; INFLAMMATION; INFLAMMATORY CELL; ISOLATED HEART; MALE; MICROELECTRODE; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE CELL ANALYSIS; SPONTANEOUSLY HYPERTENSIVE RAT; SURVIVAL; SYSTOLIC BLOOD PRESSURE; SYSTOLIC DYSFUNCTION; THORACIC AORTA; TREATMENT DURATION; VASCULAR RING;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; AGING; ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART FAILURE; HYPERTENSION; MALE; METOPROLOL; RATS; RATS, INBRED SHR; RATS, INBRED WKY; SURVIVAL RATE; VENTRICULAR REMODELING;

EID: 80053977338     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182283c78     Document Type: Article

References (53)

1. Bristow MR. b-Adrenergic receptor blockade in chronic heart failure. Circulation. 2000;101:558-569.
2. Foody JM, Farrell MH, Krumholz HM. b-Blocker therapy in heart failure. Scientific review. JAMA. 2002;287:883-889. (Pubitemid 34252037)
3. Coons JC, McGraw M, Murali S. Pharmacotherapy for acute heart failure syndromes. Am J Health-Syst Pharm. 2011;68:21-35.
4. Uddin N, Patterson JH. Current guidelines for treatment of heart failure: 2006 update. Pharmacotherapy. 2007;27(pt 2):12S-17S. (Pubitemid 46516761)
5. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol. 1997;80:26L-40L. (Pubitemid 27528445)
6. Wallukat G, Boewer V, Fö rster A, et al. Anti-b-adrenoceptor autoantibodies with b-adrenergic agonistic activity from patients with myocarditis and dilated cardiomyopathy. In: Lewis BS, Kimchi A, eds. Heart Failure Mechanisms and Management. Heidelberg, Germany: Springer Verlag; 1991:21-29.
7. Loch D, Chan V, Hoey A, et al. Rosuvastatin attenuates heart failure and cardiac remodelling in the ageing spontaneously hypertensive rat. Basic Clin Pharmacol Toxicol. 2009;105:262-270.
8. Chan V, Fenning A, Levick SP, et al. Cardiovascular changes during maturation and ageing in male and female spontaneously hypertensive rats. J Cardiovasc Pharmacol. 2011;57:469-478.
9. Bing OHL, Brooks WW, Robinson KG, et al. The spontaneously hypertensive rat as a model of the transition from compensated left ventricular hypertrophy to failure. J Mol Cell Cardiol. 1995;27:383-396.
10. Linz W, Wohlfart P, Schoelkens BA, et al. Late treatment with ramipril increases survival in old spontaneously hypertensive rats. Hypertension. 1999;34:291-295. (Pubitemid 29409230)
11. 2 agonist and a b-blocker in reducing adrenergic drive and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion. J Cardiovasc Pharmacol. 1998;31:601-608. (Pubitemid 28153139)
12. Prabhu SD, Chandrasekar B, Murray DR, et al. β-Adrenergic blockade in developing heart failure. Effects of myocardial inflammatory cytokines, nitric oxide, and remodelling. Circulation. 2000;101:2103-2109. (Pubitemid 30233176)
13. Varagic J, Susic D, Frohlich ED. Low-dose ACE with alpha- or betaadrenergic receptor inhibitors have beneficial SHR cardiovascular effects. J Cardiovasc Pharmacol Ther. 2001;6:57-63. (Pubitemid 32979888)
14. Chan V, Fenning A, Iyer A, et al. Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats. Curr Pharm Biotechnol. 2011;12:429-436.
15. Sim AS, Salonikas C, Naidoo D, et al. Improved method for plasma malondialdehyde measurement by high-performance liquid chromatography using methyl malondialdehyde as an internal standard. J Chromatogr B Anal Technol Biomed Life Sci. 2003;785:337-344. (Pubitemid 36126174)
16. Brown L, Fenning A, Chan V, et al. Echocardiographic assessment of cardiac structure and function in rats. Heart Lung Circ. 2002;11:167-173. (Pubitemid 36040767)
17. Litwin SE, Katz SE, Morgan JP, et al. Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation. 1994;89:345-354. (Pubitemid 24026509)
18. Brown L, Duce B, Miric G, et al. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system. J Am Soc Nephrol. 1999;10(suppl 11):S143-S148. (Pubitemid 29038179)
19. Chan V, Hoey A, Brown, L. Improved cardiovascular function with aminoguanidine in DOCA-salt hypertensive rats. Br J Pharmacol. 2006; 148:902-908. (Pubitemid 44543607)
20. Fenning A, Harrison G, Rose'meyer R, et al. L-Arginine attenuates cardiovascular impairment in DOCA-salt hypertensive rats. Am J Physiol. 2005;289:H1408-H1416. (Pubitemid 41368981)
21. Groenning BA, Nilsson JC, Sondergaard L, et al. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol. 2000;36:2072-2080.
22. Benetos A, Poitevin P, Prost PL, et al. Life survival and cardiovascular structures following selective b-blockade in spontaneously hypertensive rats. Am J Hypertens. 1994;7:186-192. (Pubitemid 24079129)
23. Barone FC, Willette RN, Nelson AH, et al. Carvedilol prevents and reverses hypertrophy-induced cardiac dysfunction. Pharmacology. 2007;80:166-176. (Pubitemid 47230711)
24. Blumenfeld JD, Sealey JE, Mann SJ, et al. β-Adrenergic receptor blockade as a therapeutic approach for suppressing the renin- angiotensinaldosterone system in normotensive and hypertensive subjects. Am J Hypertens. 1999;12:451-459. (Pubitemid 29238406)
25. Krum H, Gu A,Wilshire-Clement M, et al. Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure. Am Heart J. 1996;131:337-341. (Pubitemid 26043395)
26. Kobayashi M, Machida N, Tanaka R, et al. Effects of b-blocker on left ventricular remodelling in rats with volume overload cardiac failure. J Vet Med Sci. 2008;70:1231-1237.
27. Onodera T, Tamura T, Said S, et al. Maladaptive remodeling of cardiac myocyte shape begins long before failure in hypertension. Hypertension. 1998;32:753-757. (Pubitemid 28480556)
28. Nicoletti A, Heudes D, Mandet C, et al. Inflammatory cells and myocardial fibrosis: spatial and temporal distribution in renovascular hypertensive rats. Cardiovasc Res. 1996;32:1096-1107. (Pubitemid 26423399)
29. Ohtsuka T, Hamada M, Hiasa G, et al. Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2001;37:412-417.
30. 1- blockade attenuates postinfarct remodelling without improvement inmyocardial energymetabolism and function in rats with heart failure. Eur J Heart Fail. 2003;5:725-732. (Pubitemid 38198059)
31. Dunzendorfer S,Wiedermann CJ. Modulation of neutrophil migration and superoxide anion release by metoprolol. J Mol Cell Cardiol. 2000;32: 915-924. (Pubitemid 30663101)
32. Wei S, Chow LTC, Sanderson JE. Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction. J Am Coll Cardiol. 2000;36:276-281. (Pubitemid 30466145)
33. Grimm D, Huber M, Jabusch HC, et al. Extracellular matrix proteins in cardiac fibroblasts derived from rat hearts with chronic pressure overload: effects of beta-receptor blockade. J Mol Cell Cardiol. 2001;33:487-501. (Pubitemid 32539005)
34. Barrington PL, Ten Eick RE. Characterization of the electrophysiological effects of metoprolol on isolated feline ventricular myocytes. J Pharmacol Exp Ther. 1990;252:1043-1052. (Pubitemid 20127408)
35. Wagner K, Kamkin A, Kiseleva I, et al. Effects of metoprolol and ramipril on action potentials after myocardial infarction in rats. Eur J Pharmacol. 2000;388:263-266. (Pubitemid 30089850)
36. Brooksby P, Levi AJ, Jones JV. The electrophysiological characteristics of hypertrophied ventricular myocytes from the spontaneously hypertensive rat. J Hypertens. 1993;11:611-622. (Pubitemid 23225204)
37. Cerbai E, Barbieri M, Li Q, et al. Ionic basis of action potential prolongation of hypertrophied cardiac myocytes isolated from hypertensive rats of different ages. Cardiovasc Res. 1994;28:1180-1187. (Pubitemid 24264724)
38. Boyden PA, Jeck CD. Ion channel function in disease. Cardiovasc Res. 1995;29:312-318.
39. Yokoshiki H, Kohya T, Tomita F, et al. Restoration of action potential duration and transient outward current by regression of left ventricular hypertrophy. J Mol Cell Cardiol. 1997;29:1331-1339. (Pubitemid 27259647)
40. 1-adrenergic receptor antibodies and heart failure: causation, not just correlation. J Clin Invest. 2004;113:1379-1382. (Pubitemid 39071690)
41. 1- adrenoceptor. J Hypertens. 1995;13:1031-1036.
42. 1-adrenoceptor autoantibodies of spontaneously hypertensive rats. Mol Cell Biochem. 2003;251:67-75. (Pubitemid 37220711)
43. 1- adrenoceptor from patients with dilated cardiomyopathy prolong action potential duration and enhance contractility in isolated cardiomyocytes. J Mol Cell Cardiol. 2001;33:1515-1525. (Pubitemid 32681669)
44. Mulder P, Barbier S, Chagraoui A, et al. Long-term heart rate reduction induced by the selective If current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation. 2004;109:1674-1679. (Pubitemid 38451726)
45. Badenhorst D, Veliotes D, Maseko M, et al. β-Adrenergic activation initiates chamber dilatation in concentric hypertrophy. Hypertension. 2003;41:499-504. (Pubitemid 36314623)
46. Böhm M, Beuckelmann D, Diet F, et al. Properties of cardiac a- and b-adrenoceptors in spontaneously hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol. 1988;338:383-391. (Pubitemid 19002184)
47. Brown L, Ooi S, Lau K, et al. Cardiac and vascular responses in deoxycorticosterone acetate-salt hypertensive rats. Clin Exp Pharmacol Physiol. 2000;27:263-269. (Pubitemid 30194163)
48. Davel APC, Fukuda LE, De Sá LL, et al. Effects of isoproterenol treatment for 7 days on inflammatory mediators in the rat aorta. Am J Physiol. 2008;295:H211-H219.
49. Nava E, Farre AL, Moreno C, et al. Alterations to the nitric oxide pathway in the spontaneously hypertensive rat. J Hypertens. 1998;16:609-615. (Pubitemid 28230549)
50. Wu R, Millette E, Wu L, et al. Enhanced superoxide anion formation in vascular tissues from spontaneously hypertensive and deoxycorticosterone acetate-salt hypertensive rats. J Hypertens. 2001;19:741-748. (Pubitemid 32289554)
51. Hole T, Froland G, Gullestad L, et al. Metoprolol CR/XL improves systolic and diastolic left ventricular function in patients with chronic heart failure. Echocardiography. 2004;21:215-223. (Pubitemid 38478937)
52. Waagstein F, Strömblad O, Andersson B, et al. Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: a randomized, stratified, double-blind, placebocontrolled trial in mild to moderate heart failure due to ischemic or idiopathic dilated cardiomyopathy. Eur J Heart Fail. 2003;5:679-691. (Pubitemid 38043974)
53. 1- blockade improves cardiac bioenergetics and function and decreases neuroendocrine activation in rats during early postinfarct remodeling. Biochem Biophys Res Commun. 2001;281:491-498. (Pubitemid 32928182)